Neuphoria Therapeutics (NEUP) Market Capitalization (2022 - 2026)

Neuphoria Therapeutics (NEUP) has reported Market Capitalization for 5 consecutive years, with $507.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Market Capitalization fell 29.34% year-over-year to $507.4 million in Q1 2026; TTM through Mar 2026 was $507.4 million, a 29.34% decrease from a year earlier, with the FY2025 full-year figure at $879.6 million, down 22.83% from the prior year.
• Market Capitalization was $507.4 million for Q1 2026 at Neuphoria Therapeutics, up from $483.7 million in the prior quarter.
• Over five years, Market Capitalization peaked at $9.5 billion in Q2 2022 and troughed at $427.6 million in Q4 2024.
• A 5-year average of $2.1 billion and a median of $1.1 billion in 2024 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization slumped 83.73% in 2024 and surged 123.72% in 2025, its largest moves.
• Over 5 years, Market Capitalization stood at $9.5 billion in 2022, then plunged by 76.6% to $2.2 billion in 2023, then tumbled by 80.69% to $427.6 million in 2024, then rose by 13.12% to $483.7 million in 2025, then advanced by 4.9% to $507.4 million in 2026.
• The last three Market Capitalization figures came in at $507.4 million (Q1 2026), $483.7 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.